For members of the panel, I think the greater concern, as reported to them by members of the insurance industry, was the consequences, especially with small businesses that have small group plans and one employee who then develops a rare disease. Very quickly, the cost of providing those medicines swamp that business's ability to sustain that private insurance.
That is definitely a major concern and I think it's one echoed widely across the small business community and among insurers.